cloudfront

Report Detail



OtherGlobal Oncolytic Virus Immunotherapy Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

  • RnM2414326
  • |
  • 14 September, 2018
  • |
  • Global
  • |
  • 123 pages
  • |
  • GIR (Global Info Research)
  • |
  • Other

Global Oncolytic Virus Immunotherapy Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

Table of Contents

    1 Oncolytic Virus Immunotherapy Market Overview

    • 1.1 Product Overview and Scope of Oncolytic Virus Immunotherapy
    • 1.2 Classification of Oncolytic Virus Immunotherapy by Types
    • 1.2.1 Global Oncolytic Virus Immunotherapy Revenue Comparison by Types (2017-2023)
  • 1.2.2 Global Oncolytic Virus Immunotherapy Revenue Market Share by Types in 2017
  • 1.2.3 Engineering Oncolytic Viruses
  • 1.2.4 Wild-Type Oncolytic Viruses
  • 1.3 Global Oncolytic Virus Immunotherapy Market by Application
  • 1.3.1 Global Oncolytic Virus Immunotherapy Market Size and Market Share Comparison by Applications (2013-2023)
  • 1.3.2 Hospitals
  • 1.3.3 Clinics
  • 1.3.4 Ambulatory Surgical Centers
  • 1.4 Global Oncolytic Virus Immunotherapy Market by Regions
  • 1.4.1 Global Oncolytic Virus Immunotherapy Market Size (Million USD) Comparison by Regions (2013-2023)
  • 1.4.1 North America (USA, Canada and Mexico) Oncolytic Virus Immunotherapy Status and Prospect (2013-2023)
  • 1.4.2 Europe (Germany, France, UK, Russia and Italy) Oncolytic Virus Immunotherapy Status and Prospect (2013-2023)
  • 1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Oncolytic Virus Immunotherapy Status and Prospect (2013-2023)
  • 1.4.4 South America (Brazil, Argentina, Colombia) Oncolytic Virus Immunotherapy Status and Prospect (2013-2023)
  • 1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Oncolytic Virus Immunotherapy Status and Prospect (2013-2023)
  • 1.5 Global Market Size of Oncolytic Virus Immunotherapy (2013-2023)
  • 2 Manufacturers Profiles

    • 2.1 Merck
    • 2.1.1 Business Overview
  • 2.1.2 Oncolytic Virus Immunotherapy Type and Applications
  • 2.1.2.1 Product A
  • 2.1.2.2 Product B
  • 2.1.3 Merck Oncolytic Virus Immunotherapy Revenue, Gross Margin and Market Share (2016-2017)
  • 2.2 Amgen
  • 2.2.1 Business Overview
  • 2.2.2 Oncolytic Virus Immunotherapy Type and Applications
  • 2.2.2.1 Product A
  • 2.2.2.2 Product B
  • 2.2.3 Amgen Oncolytic Virus Immunotherapy Revenue, Gross Margin and Market Share (2016-2017)
  • 2.3 TILT Biotherapeutics
  • 2.3.1 Business Overview
  • 2.3.2 Oncolytic Virus Immunotherapy Type and Applications
  • 2.3.2.1 Product A
  • 2.3.2.2 Product B
  • 2.3.3 TILT Biotherapeutics Oncolytic Virus Immunotherapy Revenue, Gross Margin and Market Share (2016-2017)
  • 2.4 Oncorus
  • 2.4.1 Business Overview
  • 2.4.2 Oncolytic Virus Immunotherapy Type and Applications
  • 2.4.2.1 Product A
  • 2.4.2.2 Product B
  • 2.4.3 Oncorus Oncolytic Virus Immunotherapy Revenue, Gross Margin and Market Share (2016-2017)
  • 2.5 Sorrento Therapeutics
  • 2.5.1 Business Overview
  • 2.5.2 Oncolytic Virus Immunotherapy Type and Applications
  • 2.5.2.1 Product A
  • 2.5.2.2 Product B
  • 2.5.3 Sorrento Therapeutics Oncolytic Virus Immunotherapy Revenue, Gross Margin and Market Share (2016-2017)
  • 2.6 Shanghai Sunway Biotech
  • 2.6.1 Business Overview
  • 2.6.2 Oncolytic Virus Immunotherapy Type and Applications
  • 2.6.2.1 Product A
  • 2.6.2.2 Product B
  • 2.6.3 Shanghai Sunway Biotech Oncolytic Virus Immunotherapy Revenue, Gross Margin and Market Share (2016-2017)
  • 3 Global Oncolytic Virus Immunotherapy Market Competition, by Players

    • 3.1 Global Oncolytic Virus Immunotherapy Revenue and Share by Players (2013-2018)
    • 3.2 Market Concentration Rate
    • 3.2.1 Top 5 Oncolytic Virus Immunotherapy Players Market Share
  • 3.2.2 Top 10 Oncolytic Virus Immunotherapy Players Market Share
  • 3.3 Market Competition Trend
  • 4 Global Oncolytic Virus Immunotherapy Market Size by Regions

    • 4.1 Global Oncolytic Virus Immunotherapy Revenue and Market Share by Regions
    • 4.2 North America Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 4.3 Europe Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 4.4 Asia-Pacific Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 4.5 South America Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 4.6 Middle East and Africa Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)

    5 North America Oncolytic Virus Immunotherapy Revenue by Countries

    • 5.1 North America Oncolytic Virus Immunotherapy Revenue by Countries (2013-2018)
    • 5.2 USA Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 5.3 Canada Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 5.4 Mexico Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)

    6 Europe Oncolytic Virus Immunotherapy Revenue by Countries

    • 6.1 Europe Oncolytic Virus Immunotherapy Revenue by Countries (2013-2018)
    • 6.2 Germany Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 6.3 UK Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 6.4 France Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 6.5 Russia Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 6.6 Italy Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)

    7 Asia-Pacific Oncolytic Virus Immunotherapy Revenue by Countries

    • 7.1 Asia-Pacific Oncolytic Virus Immunotherapy Revenue by Countries (2013-2018)
    • 7.2 China Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 7.3 Japan Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 7.4 Korea Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 7.5 India Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 7.6 Southeast Asia Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)

    8 South America Oncolytic Virus Immunotherapy Revenue by Countries

    • 8.1 South America Oncolytic Virus Immunotherapy Revenue by Countries (2013-2018)
    • 8.2 Brazil Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 8.3 Argentina Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 8.4 Colombia Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)

    9 Middle East and Africa Revenue Oncolytic Virus Immunotherapy by Countries

    • 9.1 Middle East and Africa Oncolytic Virus Immunotherapy Revenue by Countries (2013-2018)
    • 9.2 Saudi Arabia Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 9.3 UAE Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 9.4 Egypt Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 9.5 Nigeria Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)
    • 9.6 South Africa Oncolytic Virus Immunotherapy Revenue and Growth Rate (2013-2018)

    10 Global Oncolytic Virus Immunotherapy Market Segment by Type

    • 10.1 Global Oncolytic Virus Immunotherapy Revenue and Market Share by Type (2013-2018)
    • 10.2 Global Oncolytic Virus Immunotherapy Market Forecast by Type (2018-2023)
    • 10.3 Engineering Oncolytic Viruses Revenue Growth Rate (2013-2023)
    • 10.4 Wild-Type Oncolytic Viruses Revenue Growth Rate (2013-2023)

    11 Global Oncolytic Virus Immunotherapy Market Segment by Application

    • 11.1 Global Oncolytic Virus Immunotherapy Revenue Market Share by Application (2013-2018)
    • 11.2 Oncolytic Virus Immunotherapy Market Forecast by Application (2018-2023)
    • 11.3 Hospitals Revenue Growth (2013-2018)
    • 11.4 Clinics Revenue Growth (2013-2018)
    • 11.5 Ambulatory Surgical Centers Revenue Growth (2013-2018)

    12 Global Oncolytic Virus Immunotherapy Market Size Forecast (2018-2023)

    • 12.1 Global Oncolytic Virus Immunotherapy Market Size Forecast (2018-2023)
    • 12.2 Global Oncolytic Virus Immunotherapy Market Forecast by Regions (2018-2023)
    • 12.3 North America Oncolytic Virus Immunotherapy Revenue Market Forecast (2018-2023)
    • 12.4 Europe Oncolytic Virus Immunotherapy Revenue Market Forecast (2018-2023)
    • 12.5 Asia-Pacific Oncolytic Virus Immunotherapy Revenue Market Forecast (2018-2023)
    • 12.6 South America Oncolytic Virus Immunotherapy Revenue Market Forecast (2018-2023)
    • 12.7 Middle East and Africa Oncolytic Virus Immunotherapy Revenue Market Forecast (2018-2023)

    13 Research Findings and Conclusion

      14 Appendix

      • 14.1 Methodology

      Oncology Immunotherapy exploits virus's ability to replicate selectively and kill tumor tissue while at the same time regulate the specific immune response of a patient The first oncolytic virus to demonstrate a clinical benefit in patients with melanoma is genetically modified herpes simplex virus type I i.e. Talimogene laherparepvec (T-VEC).

      Scope of the Report:

      This report studies the Oncolytic Virus Immunotherapy market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Oncolytic Virus Immunotherapy market by product type and applications/end industries.

      North America is leading in the oncolytic virus immunotherapy market globally, according to Skin Cancer Foundation Statistics, Globally 132,000 melanoma skin cancers occur each year. One in every three cancers diagnosed is a skin cancer, and one in every five Americans will develop skin cancer in their lifetime. North America has well-developed healthcare infrastructure with massive investment in research and development of oncolytic virus immunotherapy.

      The global Oncolytic Virus Immunotherapy market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

      The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.

      North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Oncolytic Virus Immunotherapy.

      Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

      Market Segment by Companies, this report covers

      Merck

      Amgen

      TILT Biotherapeutics

      Oncorus

      Sorrento Therapeutics

      Shanghai Sunway Biotech

      Market Segment by Regions, regional analysis covers

      North America (United States, Canada and Mexico)

      Europe (Germany, France, UK, Russia and Italy)

      Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

      South America (Brazil, Argentina, Colombia)

      Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

      Market Segment by Type, covers

      Engineering Oncolytic Viruses

      Wild-Type Oncolytic Viruses

      Market Segment by Applications, can be divided into

      Hospitals

      Clinics

      Ambulatory Surgical Centers




      Summary:
      Get latest Market Research Reports on Oncolytic Virus Immunotherapy . Industry analysis & Market Report on Oncolytic Virus Immunotherapy is a syndicated market report, published as Global Oncolytic Virus Immunotherapy Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023. It is complete Research Study and Industry Analysis of Oncolytic Virus Immunotherapy market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $3,480.00
      $5,220.00
      $6,960.00
      2,336.82
      3,505.23
      4,673.64
      3,202.30
      4,803.44
      6,404.59
      421,567.20
      632,350.80
      843,134.40
      230,770.63
      346,155.95
      461,541.26
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report